covid-19 antibody nasal spray

A COVID-19 antibody nasal spray is not a single uniquely identifiable drug name but a **non-specific category** referring to multiple intranasal antibody products intended to prevent or reduce SARS-CoV-2 infection at the nasal mucosa. These products generally contain neutralizing antibodies directed against the **SARS-CoV-2 spike protein**, formulated as sprays for **intranasal** administration to provide topical mucosal protection rather than systemic exposure. Reported examples include human monoclonal antibody sprays such as **SA55** and **MY-586**, bovine colostrum-derived antibody sprays such as **BioBlock**, and hydroxypropyl methylcellulose based human IgG1 antibody nasal sprays. The common therapeutic concept is local binding and neutralization of SARS-CoV-2 in the upper airway, potentially blocking spike interaction with host receptors and thereby serving mainly as prophylaxis or early-exposure protection for COVID-19.

Brand names

BioBlock

Other names

nasal antibody sprayanti-SARS-CoV-2 antibody nasal sprayanti-SARS-CoV2 antibody nasal sprayanti-SARS-CoV 2 antibody nasal spraySARS-CoV-2 neutralizing antibody nasal spraySARS-CoV2 neutralizing antibody nasal spraySARS-CoV 2 neutralizing antibody nasal sprayhuman anti-SARS-CoV-2 IgG1 nasal spray